Newsletter Signup | Join Community | Cancer Types
FDA Approves Checkpoint Inhibitor Targeted Immunotherapy for Treatment of Colorectal Cancer.
Cancer Connect
Targeting BRAF and EGFR Doubles Progression-free Survival in Metastatic Colorectal Cancer.
New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment
Cyramza Added to FOLFIRI Delays Disease Progression and Extends Survival for Patients With Advanced Colorectal Cancer
FOLFOX Improves Disease-Free Survival in Stage II and III Rectal Cancer Patients
Continued Avastin Extends Survival After First Progression in Advanced Colorectal Cancer
by
Noah Centineo
Aggressive Rectal Cancer More Common in Young Adults
New Treatment Identified for Locally Advanced Rectal Cancer Has Fewer Side Effects Than Current Standard
Rectal Cancer Patients May Benefit from Higher Dose of Preoperative Radiation
Pathological Complete Response Predicts Better Outcomes in Locally Advanced Rectal Cancer Patients
Rates of Adenoma Detection Linked to Risk of Interval Colorectal Cancer
Cost Versus Benefit Among Chemotherapy Drugs for Metastatic Colorectal Cancer
Low Levels of Vitamin B6 May Increase Risk of Colorectal Cancer
Combination of Erbitux® and Chemotherapy Shows Promise Against Liver Metastases
Vectibix Delays Progression of Metastatic Rectal Cancer
Addition of Preoperative Chemotherapy to Radiation Therapy Helps Preserve Sphincter Control for Rectal Cancer Patients
Radiation Plus Surgery Reduces Risk of Recurrences in Rectal Cancer
Addition of Chemotherapy to Pre-operative Radiation Improves Responses in Rectal Cancer
Neoadjuvant Therapy Superior to Adjuvant Therapy in Rectal Cancer
Radiation for Rectal Cancer Has Benefit in Spite of Increased Risk of Second Cancers
Laparoscopic Surgery Does Not Affect Survival in Colorectal Cancer
Contrast-Enhanced Endorectal MRI More Accurate than Ultrasound in Detecting Residual or Recurrent Rectal Cancer
COX-2 Expression Associated with Recurrences Following Radiation Therapy in Rectal Cancer
Second Surgery for Liver Metastases Safe in Patients with Colorectal Cancer
Radiation Therapy before Surgery for Stages I to III Rectal Cancer Improves Survival
Preoperative Radiation May Improve Survival in Patients with Stage II Rectal Cancer
Addition of Eloxatin® to Treatment for Unresectable Rectal Cancer Promising
Pre-operative Chemoradiotherapy for Rectal Cancer Improves Local Control, but Not Overall Survival
Pre-Operative Radiation Improves Survival in Early Stage Rectal Cancer
Preoperative Radiation and Chemotherapy May Improve Treatment Outcomes in Patients with Rectal Cancer
Early Versus Late Radiation with Concurrent Chemotherapy Appears Superior in Rectal Cancer
Chemo and Radiation Therapy before Surgery for Locally Advanced Rectal Cancer May Help Preserve Bowel Function
Preoperative Radiation Therapy is Effective in Intermediate Stage Rectal Cancer
Surgery for Lung Metastases may Improve Survival in Patients with Colorectal Cancer After Hepatic Resection
Erbitux® plus Camptosar® Effective in Patients with Colorectal Cancer Who Have Received Extensive Prior Therapy
Neoadjuvant Camptosar® plus Xeloda® Effective in Rectal Cancer
Erbitux®/Avastin®/Camptosar® Appears Effective in Colorectal Cancer Patients Not Responding to Camptosar Alone
Cure at Ten-year Survival Following Surgery to Remove Colon Cancer Spread to Liver
Changes in CEA Level After Surgery Linked to Outcomes in Rectal Cancer.
Prognosis Varies Among Patients with T3 Rectal Cancer
Chemotherapy Before Surgery Does Not Improve Survival in Rectal Cancer.
Panitumumab Reduces Disease Progression in Metastatic Colorectal Cancer
Further Evidence that High-Volume Hospitals Result in Improved Survival for Rectal Cancer Surgery
MRI Can Help Predict if Rectal Cancer May Be Surgically Removed.
Surgery Benefits Selected Elderly Patients with Colorectal Cancer
Elderly Rectal Cancer Patients May Benefit from Combined Chemotherapy and Radiation
Addition of MRI Does Not Improve Colorectal Cancer Follow-Up
Combination of Erbitux® and Camptosar® Improves Outcome in Metastatic Colorectal Cancer
Anemia Influences Outcomes in Patients with Rectal Cancer.
Drug Combination Decreases Recurrence Rate of Colon Polyps
Celebrex® Reduces Colon Adenomas
